Sarilumab SAR153191

DRUG2 trials

Sponsors

Sanofi

Conditions

Corona Virus InfectionGiant Cell Arteritis

Phase 3

Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA

TerminatedNCT03600805

SanofiGiant Cell Arteritis

Start: 2018-11-20End: 2020-11-24Updated: 2022-03-28

Sarilumab COVID-19

CompletedNCT04327388

SanofiCorona Virus Infection

Start: 2020-03-28End: 2020-09-02Updated: 2025-09-24

Related Papers

Population Pharmacokinetics and Exposure‐Response Analyses of Sarilumab in Patients with Polymyalgia Rheumatica

The Journal of Clinical Pharmacology2025-03-19

A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis.

2023-10-1615 citations

Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis.

2022-12-0128 citations

Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial.

2021-03-1753 citations

Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial.

2021-03-04183 citations

COVID-19 Convalescent Plasma Decreased Oxygen Requirement and Hospital Stay in COVID-19 Hospitalized Patients Including Those with Hematological Malignancies: A Report of 16 Patients

Blood2020-11-041 citations

Canakinumab to reduce deterioration of cardiac and respiratory function in SARS‐CoV‐2 associated myocardial injury with heightened inflammation (canakinumab in Covid‐19 cardiac injury: The three C study)

Clinical Cardiology2020-08-2448 citations